Cellular response and activation of apoptosis by mithramycin SK in p21WAF1-deficient HCT116 human colon carcinoma cells

Cancer Letters

Volumn 292, Issue 1, 2010, Pages 80-90

  Bataller, Marc ^a   Méndez, Carmen ^b   Salas, José A ^b   Portugal, José ^a  

^a INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

Apoptosis; Caspase 2; Cell death; HCT116 cells; P21WAF1

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; CASPASE 2; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA; MITHRAMYCIN; MITHRAMYCIN SK; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DRUG DERIVATIVE;

ANEUPLOIDY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN HCT116; CHEMOSENSITIVITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINESIS; DNA SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOSIS; PRIORITY JOURNAL; PROTEIN DEPLETION; WILD TYPE; CELL CYCLE; COLON TUMOR; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

APOPTOSIS; CASPASE 2; CELL CYCLE; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; G2 PHASE; HCT116 CELLS; HUMANS; MITOSIS; PLICAMYCIN; TUMOR CELLS, CULTURED;

EID: 77951222417     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.11.008     Document Type: Article

References (45)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
2. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 2007, 18:581-592.
3. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
4. Waldman T., Kinzler K.W., Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995, 55:5187-5190.
5. Kastan M.B., Bartek J. Cell-cycle checkpoints and cancer. Nature 2004, 432:316-323.
6. Besson A., Dowdy S.F., Roberts J.M. CDK inhibitors: cell cycle regulators and beyond. Dev. Cell. 2008, 14:159-169.
7. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 1996, 68:67-108.
8. El-Deiry W.S., Tokino T., Waldman T., Oliner J.D., Velculescu V.E., Burrell M., Hill D.E., Healy E., Rees J.L., Hamilton S.R., et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 1995, 55:2910-2919.
9. Broude E.V., Demidenko Z.N., Vivo C., Swift M.E., Davis B.M., Blagosklonny M.V., Roninson I.B. p21 (CDKN1A) is a negative regulator of p53 stability. Cell Cycle 2007, 6:1468-1471.
10. DeVita V.T.J., Hellman S., Rosenberg S.A. Cancer: Principles and Practice of Oncology 2005, Lippincott Williams & Wilkins, Philadelphia, PA.
11. Sastry M., Fiala R., Patel D.J. Solution structure of mithramycin dimers bound to partially overlapping sites on DNA. J. Mol. Biol. 1995, 251:674-689.
12. 2+ complexes with DNA. Biochemistry 1995, 34:1376-1385.
13. Barceló F., Scotta C., Ortiz-Lombardía M., Méndez C., Salas J.A., Portugal J. Entropically-driven binding of mithramycin in the minor groove of C/G-rich DNA sequences. Nucleic Acids Res. 2007, 35:2215-2226.
14. Hampshire A.J., Fox K.R. The effects of local DNA sequence on the interaction of ligands with their preferred binding sites. Biochimie 2008, 90:988-998.
15. Blume S.W., Snyder R.C., Ray R., Thomas S., Koller C.A., Miller D.M. Mithramycin inhibits Sp1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J. Clin. Invest. 1991, 88:1613-1621.
16. Jia Z., Zhang J., Wei D., Wang L., Yuan P., Le X., Li Q., Yao J., Xie K. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res. 2007, 67:4878-4885.
17. Rohr J., Méndez C., Salas J.A. The biosynthesis of aureolic group antibiotics. Bioorg. Chem. 1999, 27:41-54.
18. Blanco G., Fernández E., Fernández M.J., Braña A.F., Weissbach U., Kunzel E., Rohr J., Méndez C., Salas J.A. Characterization of two glycosyltransferases involved in early glycosylation steps during biosynthesis of the antitumor polyketide mithramycin by Streptomyces argillaceus. Mol. Gen. Genet. 2000, 262:991-1000.
19. Remsing L.L., González A.M., Nur-e-Alam M., Fernández-Lozano M.J., Braña A.F., Rix U., Oliveira M.A., Méndez C., Salas J.A., Rohr J., SK Mithramycin A novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: Three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis. J. Am. Chem. Soc. 2003, 125:5745-5753.
20. Rodríguez D., Quirós L.M., Salas J.A. MtmMII-mediated C-methylation during biosynthesis of the antitumor drug mithramycin is essential for biological activity and DNA-drug interaction. J. Biol. Chem. 2004, 279:8149-8158.
21. Wohlert S.E., Kunzel E., Machinek R., Méndez C., Salas J.A., Rohr J. The structure of mithramycin reinvestigated. J. Nat. Prod. 1999, 62:119-121.
22. Bataller M., Méndez C., Salas J.A., Portugal J. Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells. Mol. Cancer Ther. 2008, 7:2988-2997.
23. Albertini V., Jain A., Vignati S., Napoli S., Rinaldi A., Kwee I., Nur-e-Alam M., Bergant J., Bertoni F., Carbone G.M., Rohr J., Catapano C.V. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucleic Acids Res. 2006, 34:1721-1734.
24. Fibach E., Bianchi N., Borgatti M., Prus E., Gambari R. Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells. Blood 2003, 102:1276-1281.
25. Ryu H., Lee J., Hagerty S.W., Soh B.Y., McAlpin S.E., Cormier K.A., Smith K.M., Ferrante R.J. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl. Acad. Sci. USA 2006, 103:19176-19181.
26. Previdi S., Albertini V., Nur-e-Alam M., Kwee I., Broggini M., Carbone G.M., Rohr J., Catapano C.V. Antitumor activity of the new aureolic acid derivatives mithramycin SDK and SK in human ovarian cancer xenografts. Eur. J. Cancer 2006, 4(Suppl.):97. 10.1016/S1359-6349(06)70313-5.
27. Shi M., Vivian C.J., Lee K.J., Ge C., Morotomi-Yano K., Manzl C., Bock F., Sato S., Tomomori-Sato C., Zhu R., Haug J.S., Swanson S.K., Washburn M.P., Chen D.J., Chen B.P., Villunger A., Florens L., Du C. DNA-PKcs-PIDDosome: a nuclear caspase-2-activating complex with role in G2/M checkpoint maintenance. Cell 2009, 136:508-520.
28. Baptiste-Okoh N., Barsotti A.M., Prives C. Caspase 2 is both required for p53-mediated apoptosis and downregulated by p53 in a p21-dependent manner. Cell Cycle 2008, 7:1133-1138.
29. Villamarín S., Mansilla S., Ferrer-Miralles N., Priebe W., Portugal J. A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631. Eur. J. Biochem. 2003, 270:764-770.
30. Bataller M., Portugal J. Apoptosis and cell recovery in response to oxidative stress in p53-deficient prostate carcinoma cells. Arch. Biochem. Biophys. 2005, 437:151-158.
31. Mansilla S., Priebe W., Portugal J. Mitotic catastrophe results in cell death by caspase-dependent and caspase-independent mechanisms. Cell Cycle 2006, 5:53-60.
32. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
33. Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc. Natl. Acad. Sci. USA 2000, 97:4291-4296.
34. WAF1 induces stable G1 arrest in resulting tetraploid cells. Cancer Res. 2001, 61:7660-7668.
35. Krumschnabel G., Sohm B., Bock F., Manzl C., Villunger A. The enigma of caspase-2: the laymen's view. Cell Death Differ. 2009, 16:195-207.
36. Watson J.L., Hill R., Lee P.W., Giacomantonio C.A., Hoskin D.W. Curcumin induces apoptosis in HCT-116 human colon cancer cells in a p21-independent manner. Exp. Mol. Pathol. 2008, 84:230-233.
37. Sidi S., Sanda T., Kennedy R.D., Hagen A.T., Jette C.A., Hoffmans R., Pascual J., Imamura S., Kishi S., Amatruda J.F., Kanki J.P., Green D.R., D'Andrea A.A., Look A.T. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 2008, 133:864-877.
38. Koutsodontis G., Kardassis D. Inhibition of p53-mediated transcriptional responses by mithramycin A. Oncogene 2004, 23:9190-9200.
39. Wang L., Guan X., Zhang J., Jia Z., Wei D., Li Q., Yao J., Xie K. Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models. Int. J. Oncol. 2008, 33:161-167.
40. Tuck S.P., Crawford L. Characterization of the human p53 gene promoter. Mol. Cell Biol. 1989, 9:2163-2172.
41. Tapias A., Ciudad C.J., Roninson I.B., Noé V. Regulation of Sp1 by cell cycle related proteins. Cell Cycle 2008, 7:2856-2867.
42. Snyder R.C., Miller D.M. Regulation of c-myc transcription initiation and elongation. Crit. Rev. Oncog. 1992, 3:283-291.
43. Brown L., Boswell S., Raj L., Lee S.W. Transcriptional targets of p53 that regulate cellular proliferation. Crit. Rev. Eukaryot. Gene Expr. 2007, 17:73-85.
44. Fan S., Chang J.K., Smith M.L., Duba D., Fornace A.J., O'Connor P.M. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 1997, 14:2127-2136.
45. waf1/Cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999, 18:4808-4818.